(Q37883895)

24 August 2017

1 reference

title

Mechanisms and genetics of antipsychotic-associated weight gain (English)

1 reference

24 August 2017

1 reference

S L Balt

1

1 reference

24 August 2017

G P Galloway

2

1 reference

24 August 2017

M J Baggott

3

1 reference

24 August 2017

Z Schwartz

4

1 reference

24 August 2017

J Mendelson

5

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 June 2011

1 reference

Clinical Pharmacology & Therapeutics

24 August 2017

published in

1 reference

24 August 2017

volume

90

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

179-183

1 reference

Obesity as a risk factor for antipsychotic noncompliance.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Genetics of Obesity in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Molecular and anatomical determinants of central leptin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Effects of second generation antipsychotics on leptin and ghrelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Additive effects of olanzapine and melanin-concentrating hormone agonism on energy balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Pharmacological management of atypical antipsychotic-induced weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Genetics of antipsychotic treatment emergent weight gain in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Clozapine-induced weight gain: prevalence and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

Atypical depression: a valid subtype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

7 January 2021

Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

7 January 2021

Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

7 January 2021

Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.97

7 January 2021

Identifiers

DOI

10.1038/CLPT.2011.97

1 reference

24 August 2017

1 reference